Bevacizumab Biosimilar - Ultra Low Endotoxin

Bevacizumab Biosimilar - Ultra Low Endotoxin, Host: Humanized, Human IgG1

Target: VEGF

Specificity: Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Bevacizumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Bevacizumab biosimilar is vascular endothelial growth factor directed antibody. Bevacizumab biosimilar is a recombinant humanized monoclonal IgG1 antibody that contains human framework regions and murine complementarity-determining regions. Bevacizumab biosimilar has an approximate molecular weight of 149 kDa. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium.

Concentration: 1.0 - 5.0 mg/ml

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC

Endotoxin: ≤ 0.1 EU/mg as determined by the LAL method

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• SKU: ICH4003UL-1mg
• Manufacturer: Ichorbio
• Manufacturer SKU: ICH4003UL-1mg
• Package Unit: 1mg
• Quantity Unit: STK
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: Human IgG1
• Host: Human